发布求助
文献互助 智能选刊 最新文献

Allergy最新文献

筛选
英文 中文
Sequential immunotherapy: towards cures for autoimmunity 序贯免疫疗法：迈向自身免疫疾病的治疗之路
IF 122.7 1区 医学
Allergy Pub Date : 2024-06-05 DOI: 10.1038/s41573-024-00959-8
Francisco Ramírez-Valle, Joseph C. Maranville, Sophie Roy, Robert M. Plenge
{"title":"Sequential immunotherapy: towards cures for autoimmunity","authors":"Francisco Ramírez-Valle, Joseph C. Maranville, Sophie Roy, Robert M. Plenge","doi":"10.1038/s41573-024-00959-8","DOIUrl":"10.1038/s41573-024-00959-8","url":null,"abstract":"Despite major progress in the treatment of autoimmune diseases in the past two decades, most therapies do not cure disease and can be associated with increased risk of infection through broad suppression of the immune system. However, advances in understanding the causes of autoimmune disease and clinical data from novel therapeutic modalities such as chimeric antigen receptor T cell therapies provide evidence that it may be possible to re-establish immune homeostasis and, potentially, prolong remission or even cure autoimmune diseases. Here, we propose a ‘sequential immunotherapy’ framework for immune system modulation to help achieve this ambitious goal. This framework encompasses three steps: controlling inflammation; resetting the immune system through elimination of pathogenic immune memory cells; and promoting and maintaining immune homeostasis via immune regulatory agents and tissue repair. We discuss existing drugs and those in development for each of the three steps. We also highlight the importance of causal human biology in identifying and prioritizing novel immunotherapeutic strategies as well as informing their application in specific patient subsets, enabling precision medicine approaches that have the potential to transform clinical care. Advances in understanding of the cause of autoimmune diseases and clinical data from novel therapeutic modalities such as chimeric antigen receptor T cells are providing evidence that it may be possible to re-establish immune homeostasis and, potentially, prolong remission or even cure autoimmune diseases. This article proposes a three-step ‘sequential immunotherapy’ framework for immune system modulation to help achieve this ambitious goal, and discusses existing drugs and those in development for each of the three steps.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 7","pages":"501-524"},"PeriodicalIF":122.7,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141251594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing accuracy of AlphaFold2 评估 AlphaFold 的准确性2
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-31 DOI: 10.1038/d41573-024-00090-8
Sarah Crunkhorn
{"title":"Assessing accuracy of AlphaFold2","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00090-8","DOIUrl":"10.1038/d41573-024-00090-8","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 7","pages":"499-499"},"PeriodicalIF":122.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141182346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The changing landscape of cancer cell therapies: clinical trials and real-world data 不断变化的癌症细胞疗法：临床试验和真实世界数据
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-31 DOI: 10.1038/d41573-024-00094-4
Ana Rosa Saez-Ibañez,  Samik Upadhaya,  Tanya Partridge,  Daniel Winkelman,  Diego Correa,  Jay Campbell
{"title":"The changing landscape of cancer cell therapies: clinical trials and real-world data","authors":"Ana Rosa Saez-Ibañez, \u0000 Samik Upadhaya, \u0000 Tanya Partridge, \u0000 Daniel Winkelman, \u0000 Diego Correa, \u0000 Jay Campbell","doi":"10.1038/d41573-024-00094-4","DOIUrl":"10.1038/d41573-024-00094-4","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 10","pages":"736-737"},"PeriodicalIF":122.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141182444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting ligand–protein interactions 预测配体与蛋白质之间的相互作用
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-31 DOI: 10.1038/d41573-024-00093-5
Sarah Crunkhorn
{"title":"Predicting ligand–protein interactions","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00093-5","DOIUrl":"10.1038/d41573-024-00093-5","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 7","pages":"499-499"},"PeriodicalIF":122.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141182353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Designing reversible anticoagulants 设计可逆抗凝剂
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-31 DOI: 10.1038/d41573-024-00091-7
Sarah Crunkhorn
{"title":"Designing reversible anticoagulants","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00091-7","DOIUrl":"10.1038/d41573-024-00091-7","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 7","pages":"499-499"},"PeriodicalIF":122.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141182436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reducing seizures with senolytic drugs 用解痉药物减少癫痫发作
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-31 DOI: 10.1038/d41573-024-00092-6
Sarah Crunkhorn
{"title":"Reducing seizures with senolytic drugs","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00092-6","DOIUrl":"10.1038/d41573-024-00092-6","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 7","pages":"499-499"},"PeriodicalIF":122.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141182349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug discovery for ageing: SIMPs, NEDs and screening challenges 老龄化药物发现：SIMPs、NEDs 和筛选挑战
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-29 DOI: 10.1038/d41573-024-00087-3
Richard G. A. Faragher,  Richard C. Hartley
{"title":"Drug discovery for ageing: SIMPs, NEDs and screening challenges","authors":"Richard G. A. Faragher, \u0000 Richard C. Hartley","doi":"10.1038/d41573-024-00087-3","DOIUrl":"10.1038/d41573-024-00087-3","url":null,"abstract":"Drugs that modulate fundamental mechanisms of ageing offer the promise of substantially improving the health of ageing populations, but innovative approaches to identify and evaluate such ‘gerotherapeutics’ are needed. Drugs that modulate fundamental mechanisms of ageing offer the promise of substantially improving the health of ageing populations, but innovative approaches to identify and evaluate such ‘gerotherapeutics’ are needed.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 10","pages":"725-726"},"PeriodicalIF":122.7,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141165365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-acting GLP-1 conjugate enhances weight loss 双效 GLP-1 结合物能增强减肥效果
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-29 DOI: 10.1038/d41573-024-00089-1
Sarah Crunkhorn
{"title":"Dual-acting GLP-1 conjugate enhances weight loss","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00089-1","DOIUrl":"10.1038/d41573-024-00089-1","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 7","pages":"495-495"},"PeriodicalIF":122.7,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141165196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer 美国食品和药物管理局批准首个用于肺癌的 DLL3 × CD3 双特异性 T 细胞吸引器
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-24 DOI: 10.1038/d41573-024-00088-2
Asher Mullard
{"title":"FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer","authors":"Asher Mullard","doi":"10.1038/d41573-024-00088-2","DOIUrl":"10.1038/d41573-024-00088-2","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 7","pages":"487-487"},"PeriodicalIF":122.7,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141092198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape 加速欧盟临床试验（ACT EU）：改变欧盟临床试验格局。
IF 122.7 1区 医学
Allergy Pub Date : 2024-05-23 DOI: 10.1038/d41573-024-00085-5
Giacomo Capone,  Björn Eriksson,  Monique Al,  Stan van Belkum,  Karl Broich,  Maria Lamas,  Marianne Lunzer,  Lorraine Nolan,  Catriona Ester,  Juan Garcia Burgos,  Laura Pioppo,  Ana Zanoletty,  Peter Arlett
{"title":"Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape","authors":"Giacomo Capone, \u0000 Björn Eriksson, \u0000 Monique Al, \u0000 Stan van Belkum, \u0000 Karl Broich, \u0000 Maria Lamas, \u0000 Marianne Lunzer, \u0000 Lorraine Nolan, \u0000 Catriona Ester, \u0000 Juan Garcia Burgos, \u0000 Laura Pioppo, \u0000 Ana Zanoletty, \u0000 Peter Arlett","doi":"10.1038/d41573-024-00085-5","DOIUrl":"10.1038/d41573-024-00085-5","url":null,"abstract":"Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials. Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"23 11","pages":"797-798"},"PeriodicalIF":122.7,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信